TW201823235A - 西克里維羅(cenicriviroc)甲磺酸鹽之固體型式和製造西克里維羅甲磺酸鹽之固體型式的方法 - Google Patents

西克里維羅(cenicriviroc)甲磺酸鹽之固體型式和製造西克里維羅甲磺酸鹽之固體型式的方法 Download PDF

Info

Publication number
TW201823235A
TW201823235A TW106129555A TW106129555A TW201823235A TW 201823235 A TW201823235 A TW 201823235A TW 106129555 A TW106129555 A TW 106129555A TW 106129555 A TW106129555 A TW 106129555A TW 201823235 A TW201823235 A TW 201823235A
Authority
TW
Taiwan
Prior art keywords
crystalline form
msoh
compound
patent application
scope
Prior art date
Application number
TW106129555A
Other languages
English (en)
Chinese (zh)
Inventor
帕斯特 菲雅思維薩
馬丁 庫柏
艾瑪 夏普
Original Assignee
美商托彼拉治療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商托彼拉治療公司 filed Critical 美商托彼拉治療公司
Publication of TW201823235A publication Critical patent/TW201823235A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW106129555A 2016-08-31 2017-08-30 西克里維羅(cenicriviroc)甲磺酸鹽之固體型式和製造西克里維羅甲磺酸鹽之固體型式的方法 TW201823235A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662382153P 2016-08-31 2016-08-31
US62/382,153 2016-08-31

Publications (1)

Publication Number Publication Date
TW201823235A true TW201823235A (zh) 2018-07-01

Family

ID=61241572

Family Applications (1)

Application Number Title Priority Date Filing Date
TW106129555A TW201823235A (zh) 2016-08-31 2017-08-30 西克里維羅(cenicriviroc)甲磺酸鹽之固體型式和製造西克里維羅甲磺酸鹽之固體型式的方法

Country Status (13)

Country Link
US (1) US10301287B2 (https=)
EP (1) EP3506896A4 (https=)
JP (2) JP2019526628A (https=)
KR (1) KR20190057066A (https=)
CN (1) CN110167550A (https=)
AU (1) AU2017321594A1 (https=)
BR (1) BR112019003987A2 (https=)
CA (1) CA3034606A1 (https=)
MX (1) MX2019002057A (https=)
RU (1) RU2019109019A (https=)
SG (1) SG11201901438VA (https=)
TW (1) TW201823235A (https=)
WO (1) WO2018045043A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019238041A1 (zh) * 2018-06-12 2019-12-19 南京明德新药研发有限公司 一种丙烯酰胺类化合物的晶型及其制备方法
WO2019245517A1 (en) * 2018-06-18 2019-12-26 Hewlett-Packard Development Company, L.P. Three-dimensional printing
US11613670B2 (en) 2018-06-18 2023-03-28 Hewlett-Packard Development Company, L.P. Three-dimensional printing
US11298876B2 (en) 2018-06-19 2022-04-12 Hewlett-Packard Development Company, L.P. Three-dimensional printing
US11591486B2 (en) 2018-06-19 2023-02-28 Hewlett-Packard Development Company, L.P. Three-dimensional printing
US11426931B2 (en) 2018-06-19 2022-08-30 Hewlett-Packard Development Company, L.P. Three-dimensional printing
KR20210053921A (ko) * 2018-08-31 2021-05-12 에보니크 오퍼레이션즈 게엠베하 중합체 분말을 제조하는 방법
WO2021133811A1 (en) 2019-12-26 2021-07-01 Teva Pharmaceuticals International Gmbh Solid state forms of cenicriviroc and process for preparation thereof
US12466817B2 (en) 2020-05-22 2025-11-11 Nicoya Therapeutics (Shanghai) Co., Ltd Pyridine derivative and application thereof
US20240124690A1 (en) * 2021-02-22 2024-04-18 Asahi Kasei Kabushiki Kaisha Composition Containing Cellulose Nanofibers

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62265270A (ja) 1986-05-13 1987-11-18 Zeria Shinyaku Kogyo Kk 新規イミダゾ−ル誘導体およびそれらを有効成分とする抗潰瘍剤
CA2191980A1 (en) 1994-07-04 1996-01-18 Takashi Sohda Phosphonic acid compounds, their production and use
US6172061B1 (en) 1997-12-19 2001-01-09 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative
AU5301599A (en) 1998-08-20 2000-03-14 Takeda Chemical Industries Ltd. Quaternary ammonium salts and their use
AU6870600A (en) 1999-09-06 2001-04-10 Takeda Chemical Industries Ltd. Process for the preparation of 2,3-dihydroazepine compounds
PE20030329A1 (es) 2001-08-08 2003-05-12 Takeda Chemical Industries Ltd Compuesto biciclico con actividad antagonista de ccr5 y produccion del mismo
JP2004123694A (ja) * 2002-03-12 2004-04-22 Takeda Chem Ind Ltd 光学活性スルホキシド誘導体の製造法
WO2005089714A1 (ja) 2004-03-24 2005-09-29 Takeda Pharmaceutical Company Limited エマルション安定化製剤
JP2007269628A (ja) * 2004-05-28 2007-10-18 Takeda Chem Ind Ltd 医薬化合物の結晶
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
CN103402998B (zh) 2010-11-18 2017-09-26 耶鲁大学 具有募集抗体并对人体免疫缺陷病毒进入有抑制活性的双功能分子
JP2015520144A (ja) 2012-05-11 2015-07-16 アクロン・モレキュールズ・アクチェンゲゼルシャフトAkron Molecules Ag 疼痛の治療のための化合物の使用
CN105263498B (zh) 2013-05-15 2019-04-26 妥必徕疗治公司 赛尼克韦罗组合物及其制备和使用方法
HK1232147A1 (zh) 2014-03-21 2018-01-05 Tobira Therapeutics, Inc. 用於治疗纤维化的赛尼克韦罗
US20170105969A1 (en) * 2014-06-02 2017-04-20 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of hiv-2 infection
JP6716568B2 (ja) 2014-12-23 2020-07-01 トビラ セラピューティクス, インコーポレイテッド セニクリビロックの製造方法及び関連類似体

Also Published As

Publication number Publication date
EP3506896A4 (en) 2020-08-26
EP3506896A1 (en) 2019-07-10
CA3034606A1 (en) 2018-03-08
WO2018045043A1 (en) 2018-03-08
CN110167550A (zh) 2019-08-23
RU2019109019A3 (https=) 2021-08-23
BR112019003987A2 (pt) 2019-05-28
KR20190057066A (ko) 2019-05-27
JP2019526628A (ja) 2019-09-19
JP2022137223A (ja) 2022-09-21
SG11201901438VA (en) 2019-03-28
MX2019002057A (es) 2019-11-18
US20180057481A1 (en) 2018-03-01
US10301287B2 (en) 2019-05-28
RU2019109019A (ru) 2020-10-01
AU2017321594A1 (en) 2019-04-18

Similar Documents

Publication Publication Date Title
TW201823235A (zh) 西克里維羅(cenicriviroc)甲磺酸鹽之固體型式和製造西克里維羅甲磺酸鹽之固體型式的方法
JP6081763B2 (ja) ダサチニブ多形体およびその調製プロセス
US11149017B2 (en) Solid state forms of apalutamide
EA034409B1 (ru) Способы получения кристаллического фенилацетата l-орнитина
RU2704795C2 (ru) Кристаллическая форма бисульфата ингибитора jak и способ ее получения
WO2011095059A1 (zh) 达沙替尼多晶型物及其制备方法和药物组合物
US12209073B2 (en) Polymorphs of a dihydroorotate dehydrogenase (DHOD) inhibitor
WO2021143841A1 (zh) 三并环类pde3/pde4双重抑制剂化合物的药物组合物
JP2005298424A (ja) エパルレスタット結晶の製造方法
TW202545917A (zh) N-[(1s,2e)-1-環丙基-3-(甲磺醯基)丙-2-烯-1-基]-2-(1,1-二氟乙基)-4-苯氧基嘧啶-5-甲醯胺的新固體形式
EP4486458A1 (en) Crystalline forms of trilaciclib and trilaciclib salts
KR20190029601A (ko) 고체 형태의 ttk 억제제
US20140073791A1 (en) Novel salts of sitagliptin, process for the preparation and pharmaceutical composition thereof
US7655800B2 (en) Crystalline 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)-methyl]-1H-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses
EP4477652A1 (en) Polymorph as thyroid hormone receptor agonists and use thereof
TW202434600A (zh) 磺醯胺衍生物結晶形式及其製備方法
WO2019086008A1 (zh) 一种苯并三氮唑衍生物的晶型及其制备方法和用途
WO2024179558A1 (zh) Pirtobrutinib的晶型及其制备方法和用途
TW202543633A (zh) 喹唑啉酮衍生物的晶型及其製備方法和應用
TW202606690A (zh) 吡啶并吡唑衍生物的晶型物、藥物組合物及其用途
KR20260032991A (ko) (3r)-n-[2-시아노-4-플루오로-3-(3-메틸-4-옥소-퀴나졸린-6-일)옥시-페닐]-3-플루오로-피롤리딘-1-설폰아미드의신규 고체 형태
WO2025002335A1 (zh) Baxdrostat的晶型及其制备方法和用途
TW202333694A (zh) 稠環衍生物的晶型、其製備方法及其應用
WO2009007853A2 (en) Novel polymorphs of darifenacin free base and its hydrobromide salt
CN117980295A (zh) 一种依洛西巴特晶型ii及其制备方法